DOCSLIB.ORG

Immunological Mechanisms in Drug-Induced Blood Dyscrasias

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunological Mechanisms in Drug-Induced Blood Dyscrasias J Clin Pathol: first published as 10.1136/jcp.s3-9.1.46 on 1 January 1975. Downloaded from J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 46-49 Immunological mechanisms in drug-induced blood dyscrasias URS NYDEGGER AND PETER A. MIESCHER From the Division of Haematology, Department of Medicine, University of Geneva, Geneva, Switzerland Drugs can produce blood disorders in many ways. age in Sedormid-(allylisopropylcarbamide)-induced At one end of the spectrum are dose-dependent thrombocytopenia might be mediated by Sedormid/ effects which can be explained in pharmacological antibody complexes, although at that time he came terms as 'toxic' reactions. At the other end of the to a different conclusion. Soon after, Moeschlin and spectrum are dose-independent effects which cannot Wagner (1952) observed analogous in-vitro pheno- be predicted. With the discovery of the causal rela- mena with the serum of a patient suffering from tionship between amidopyrine intake and agranulo- amidopyrine-induced agranulocytosis, but again the cytosis in certain patients, increasing attention has pathogenesis underlying this observation was inter- been paid to the latter phenomena and a number of preted in a different way. Shulman's studies (1958), distinct immune mechanisms have been elucidated as well as our own (Miescher, 1955), have suggested in drug-induced blood dyscrasias. that formation of immune complexes and their sub- The first mechanism is similar to that encountered sequent deposition on the cells are most likely to be in experimental serum sickness (Cochrane and operative in this type of cytopenia although a Koffler, 1973). The thrombocytopenia and leuco- number of pertinent questions are stilJ unanswered: penia in this condition is probably due to the effect 1 Why should one particular drug always pro- of immune complexes on the cells: platelets and duce thrombocytopenia when complexed with an leucocytes, coated with antigen-antibody complexes, antibody and another drug always produce agranu- are eliminated from the circulating blood, pre- locytosis ? sumably through phagocytosis by the reticuloendo- 2 Why is the disappearance of platelets or leuco- thelial system (Miescher, 1955; Mannick cytes from the peripheral blood almost complete, as- Haakenstad, and Arend, 1974). A similar immune- whereas experimental serum sickness is only http://jcp.bmj.com/ complex type mechanism is likely to be operative in sociated with a slight degree of thrombocytopenia many cases of drug-induced thrombocytopenia and and leucopenia? leucopenia. 3 Why are the precursor cells within the bone The second mechanism has been used for many marrow affected so greatly in this type of agranulo- years as a serological tool for the detection of anti- cytosis ? bodies and is the agglutination of antigen-coated red Various observations might help to answer the cells by antibody (passive hemagglutination). fiist question. In the case of Sedormid, it was shown Damage to drug-coated cells by drug-specific anti- that the drug concentrated around platelets without on October 2, 2021 by guest. Protected copyright. bodies is today a well recognized mechanism in being strongly attached. Furthermore, it was shown certain drug-induced cytopenias. that the drug could be washed off the platelets very A third mechanism emerged from the clinical easily. This affinity of Sedormid for platelets may observation that certain drugs lead to the develop- favour the attachment of the drug-antibody-com- ment of autoantibodies, ie, antibodies directed to plexes to the cells. In the case of drugs shown to autologous antigenic determinants. induce thrombocytopenia in some patients and im- In this review, these three mechanisms are dis- mune haemolytic anaemia in others, Shulman (1963) cussed first and serological methods available for was able to demonstrate that thrombocytopenia was diagnosis of immune drug-induced blood dyscrasias usually mediated by IgG antidrug antibodies where- will be discussed later. as immune haemolytic anaemia was usually mediated by IgM antidrug antibodies. From this observation Inmune-complex-mediated Cell Damage it was suggested that the type of antibody involved in the formation of immune complexes may also be In 1949, Ackroyd (1964, review) discovered a number relevant for the cell specificity of the reaction and it of in-vitro reactions suggesting that platelet dam- might be postulated that this specificity is related to 46 J Clin Pathol: first published as 10.1136/jcp.s3-9.1.46 on 1 January 1975. Downloaded from Immunological mechanisms in drug-induced blood dyscrasias 47 the cell surface receptors (Nussenzweig, Lay, and antibodies are involved in this type of immune Miescher, 1969). However, this question is still haemolytic anaemia (Levine et al, 1966). The anti- wide open to further investigation, particularly when bodies thus appear not to react with antigenic deter- drugs are the antigen or the hapten involved. minants on the red cell. Very similar pathogenetic The question of why granulocytes and/or platelets events seem to be operative in cephalothin-(Keflin) almost totally disappear from the peripheral blood in induced haemolytic anaemia (Gralnick, McGinnis, drug-induced agranulocytosis and/or thrombocyto- Elton, and McCurdy, 1971). The red cell appears to penia and are frequently associated with a gradual be damaged by cephalothin bound onto its surface disappearance of the precursor cells is equally diffi- and is then destroyed following the union of circulat- cult to answer. In this context, one should bear in ing anticephalothin antibody with the antigen. For mind that agents which raise the intracellular level clinical purposes it is important to know that the of cyclic AMP, such as theophyllin or prostaglandin incidence of penicillin-induced haemolytic anaemia El, have been implicated in additional damage to is much commoner than that of cephalothin-induced subcellular organelles (Gillespie, 1971). Thus drug/ anaemia and ranks at the top of a series of some 15 antibody complexes might be harmful to blood cells drugs incriminated in immune red cell damage through at least two pathways, first because the (review in Miescher, 1973). complex coats the cells and secondly because of the More recently, it has been shown that cephalothin potentiated toxic effect of the antigen. can lead to thrombocytopenia. Gralnick, McGinnis, The removal of large quantities of cells from the and Halterman (1972) were able to detect a cephalo- circulating blood with special procedures (leuco- thin-specific antibody in a well studied patient suffer- pheresis, thrombocytopheresis) does not lead to ing from cephalothin-induced thrombocytopenia. damage to the precursor cells and, in experimental When cephalothin was added to the patient's plate- serum sickness, neutropenia is not accompanied by lets, her serum agglutinated her in-vitro cephalothin- damage to the cells in the bone marrow. However, in coated platelets but not her own uncoated platelets. many drug-induced leucopenias, drug-mediated This activity could be neutralized by prior incuba- damage is not limited to circulating cells but affects tion of the serum with cephalothin. This latter precursor cells as well. The pathogenesis of the bone experiment distinguishes this type of mechanism marrow damage has not yet been elucidated but a from the immune complex type of damage in which number of differing mechanisms may be operative. a preformed complex produces agglutination The recovery time of agranulocytosis not only varies (Pfueller and Luischer, 1972). with the extent of cell damage in the bone marrow (injury to myelocytes, promyelocytes or myelo- Drug-induced Autoimmune Phenomena blasts), but also with the pharmacological variety of http://jcp.bmj.com/ drugs involved, ie, being relatively short with amido- The association of certain drugs, eg, hydralazine, pyrine and much longer with phenothiazines. procainamide, with antinuclear antibodies has lead to the assumption that the two events are causally Damage to Drug-coated Cells by Drug-specific related (Perry and Schroeder, 1954; Blomgren, Antibodies Condemi, Bignall, and Vaughan, 1969). Indeed, when procainamide medication is discontinued in This mechanism was first demonstrated in penicillin- patients taking this drug and exhibiting an SLE-like induced immune haemolytic anaemia. Evidence has syndrome, antinuclear antibody and clinical symp- on October 2, 2021 by guest. Protected copyright. been provided that part of the immunogenicity of toms and signs of SLE gradually disappear benzylpenicillin is due to a rearrangement of its (Blomgren et al, 1969). Subsequently, this observa- isomer D-benzylpenicillenic acid, a compound which tion was extended to other autoantibodies as well is chemically highly reactive with proteins. Levine and in particular to antibodies directed against and Redmond (1967) could demonstrate that 30% antigenic determinants located on the membrane of of patients taking 1-2-2-4 million units of penicillin red cells. had some detectable drug on their red cells and all Indeed, with the introduction of methyldopa into patients taking 10 or more million units had large the treatment of hypertension, this mechanism was amounts of the drug on their cells. In patients who firmly established. In fact, about 20% of patients have developed a high titre of IgG antibodies to receiving this drug for many months have been benzylpenicilloyl haemolytic anaemia occurs as a shown to develop a positive IgG Coombs test which consequence of the reaction
Load more

Recommended publications
  • Transfusion Problems in Hemolytic Anemias*
    Transfusion Problems in Hemolytic Anemias* ALI A. HOSSAIN! Department of Pathdlogy, Medical College of Virginia, Richmond 23219 All hemolytic anemias feature shortened red cell Extrinsic Mechanisms survival due to premature hemolysis of the cell. For the Those hemolytic anemias which are due to extrinsic purposes of this presentation, we may classify the factors may be classified, further, as non-immune or hemolytic anemias, most broadly, according to the immune. Non-immune mechanisms include a) drugs mechanisms leading to hemolysis. and chemicals (phenylhydrazine, naphthalene, lead, snake venoms); b) physical agents (heat); c) bacteria Intrinsic Mechanisms and parasites (hemolytic streptococci, Clostridium Hemolytic anemias due to intrinsically defective welchii, Bartonella, plasmodia); and d) acquired sen­ erythrocytes are essentially of three types. First are sitivity to penicillin, methylodopa, Keftin®, or fava those anemias in which the red cells are defective due plant as examples. Some of the agents in this. last to lack of an essential factor, eg, pernicious anemia group serve to lyse the cells, either through duect in relapse. The second type includes those in which action or by formation of antibodies. the red cells have an abnormal shape because of an These hemolytic anemias due to extrinsic factors inherited error in the chemical makeup of the hemo­ of the non-immune variety present no transfusion globin molecules; eg, sickle cells, elliptocytes, sphero­ problem for the Blood Bank. However, it ~~st b.e cytes, and the target
    [Show full text]
  • Hemolytic Disease of the Newborn
    Intensive Care Nursery House Staff Manual Hemolytic Disease of the Newborn INTRODUCTION and DEFINITION: Hemolytic Disease of the Newborn (HDN), also known as erythroblastosis fetalis, isoimmunization, or blood group incompatibility, occurs when fetal red blood cells (RBCs), which possess an antigen that the mother lacks, cross the placenta into the maternal circulation, where they stimulate antibody production. The antibodies return to the fetal circulation and result in RBC destruction. DIFFERENTIAL DIAGNOSIS of hemolytic anemia in a newborn infant: -Isoimmunization -RBC enzyme disorders (e.g., G6PD, pyruvate kinase deficiency) -Hemoglobin synthesis disorders (e.g., alpha-thalassemias) -RBC membrane abnormalities (e.g., hereditary spherocytosis, elliptocytosis) -Hemangiomas (Kasabach Merritt syndrome) -Acquired conditions, such as sepsis, infections with TORCH or Parvovirus B19 (anemia due to RBC aplasia) and hemolysis secondary to drugs. ISOIMMUNIZATION A. Rh disease (Rh = Rhesus factor) (1) Genetics: Rh positive (+) denotes presence of D antigen. The number of antigenic sites on RBCs varies with genotype. Prevalence of genotype varies with the population. Rh negative (d/d) individuals comprise 15% of Caucasians, 5.5% of African Americans, and <1% of Asians. A sensitized Rh negative mother produces anti-Rh IgG antibodies that cross the placenta. Risk factors for antibody production include 2nd (or later) pregnancies*, maternal toxemia, paternal zygosity (D/D rather than D/d), feto-maternal compatibility in ABO system and antigen load. (2) Clinical presentation of HDN varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions). Because the placenta clears bilirubin, the chief risk to the fetus is anemia. Extramedullary hematopoiesis (due to anemia) results in hepatosplenomegaly.
    [Show full text]
  • A Newly Recognized Blood Group in Domestic Shorthair Cats: the Mik Red Cell Antigen
    J Vet Intern Med 2007;21:287–292 A Newly Recognized Blood Group in Domestic Shorthair Cats: The Mik Red Cell Antigen Nicole M. Weinstein, Marie-Claude Blais, Kimberly Harris, Donna A. Oakley, Lillian R. Aronson, and Urs Giger Background: Naturally occurring alloantibodies produced against A and B red cell antigens in cats can cause acute hemolytic transfusion reactions. Blood incompatibilities, unrelated to the AB blood group system, have also been suspected after blood transfusions through routine crossmatch testing or as a result of hemolytic transfusion reactions. Hypothesis: Incompatible crossmatch results among AB compatible cats signify the presence of a naturally occurring alloantibody against a newly identified blood antigen in a group of previously never transfused blood donor cats. The associated alloantibody is clinically important based upon a hemolytic transfusion reaction after inadvertent transfusion of red cells expressing this red cell antigen in a feline renal transplant recipient that lacks this red cell antigen. Methods: Blood donor and nonblood donor cats were evaluated for the presence of auto- and alloantibodies using direct antiglobulin and crossmatch tests, respectively, and were blood typed for AB blood group status. Both standard tube and novel gel column techniques were used. Results: Plasma from 3 of 65 cats and 1 feline renal transplant recipient caused incompatible crossmatch test results with AB compatible erythrocytes indicating these cats formed an alloantibody against a red cell antigen they lack, termed Mik. The 3 donors and the renal transplant recipient were crossmatch-compatible with one another. Tube and gel column crossmatch test results were similar. Conclusions and Clinical Importance: The absence of this novel Mik red cell antigen can be associated with naturally occurring anti-Mik alloantibodies and can elicit an acute hemolytic transfusion reaction after an AB-matched blood transfusion.
    [Show full text]
  • Blood Bank I D
    The Osler Institute Blood Bank I D. Joe Chaffin, MD Bonfils Blood Center, Denver, CO The Fun Just Never Ends… A. Blood Bank I • Blood Groups B. Blood Bank II • Blood Donation and Autologous Blood • Pretransfusion Testing C. Blood Bank III • Component Therapy D. Blood Bank IV • Transfusion Complications * Noninfectious (Transfusion Reactions) * Infectious (Transfusion-transmitted Diseases) E. Blood Bank V (not discussed today but available at www.bbguy.org) • Hematopoietic Progenitor Cell Transplantation F. Blood Bank Practical • Management of specific clinical situations • Calculations, Antibody ID and no-pressure sample questions Blood Bank I Blood Groups I. Basic Antigen-Antibody Testing A. Basic Red Cell-Antibody Interactions 1. Agglutination a. Clumping of red cells due to antibody coating b. Main reaction we look for in Blood Banking c. Two stages: 1) Coating of cells (“sensitization”) a) Affected by antibody specificity, electrostatic RBC charge, temperature, amounts of antigen and antibody b) Low Ionic Strength Saline (LISS) decreases repulsive charges between RBCs; tends to enhance cold antibodies and autoantibodies c) Polyethylene glycol (PEG) excludes H2O, tends to enhance warm antibodies and autoantibodies. 2) Formation of bridges a) Lattice structure formed by antibodies and RBCs b) IgG isn’t good at this; one antibody arm must attach to one cell and other arm to the other cell. c) IgM is better because of its pentameric structure. P}Chaffin (12/28/11) Blood Bank I page 1 Pathology Review Course 2. Hemolysis a. Direct lysis of a red cell due to antibody coating b. Uncommon, but equal to agglutination. 1) Requires complement fixation 2) IgM antibodies do this better than IgG.
    [Show full text]
  • Autoimmune Hemolytic Anemia in COVID-19 Patients, the « Transmissible » Direct Coombs Test
    J H C R JOURNAL OF HEMATOLOGY 2640-2823 AND CLINICAL RESEARCH Research Article More Information *Address for Correspondence: Alice Brochier, Hematology Department of Laboratory Medicine, Autoimmune hemolytic anemia in Saint-Luc University Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium, Tel: +322764 6814; COVID-19 patients, the « transmissible » Email: [email protected]; Véronique Deneys, Hematology Department of Laboratory Medicine, Saint-Luc University direct Coombs test Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium, Email: [email protected] Alice Brochier1*, Julien Cabo1, Claudine Guerrieri1, Leïla Belkhir2, Submitted: March 24, 2021 3 1 Pierre-François Laterre and Véronique Deneys * Approved: April 06, 2021 Published: April 07, 2021 1Hematology Department of Laboratory Medicine, Saint-Luc University Hospital, Brussels, Belgium 2Department of Internal Medicine and Infectious Diseases, Saint-Luc University Hospital, Brussels, How to cite this article: Brochier A, Cabo J, Guerrieri C, Belkhir L, Laterre PF, Deneys V. Belgium Autoimmune hemolytic anemia in COVID-19 3 Department of Intensive Care Medicine, Saint-Luc University Hospital, Brussels, Belgium patients, the « transmissible » direct Coombs test. J Hematol Clin Res. 2021; 5: 004-008. Abstract DOI: 10.29328/journal.jhcr.1001016 Copyright: © 2021 Brochier A, et al. This Background: Like other viruses, the SARS-CoV-2 (severe acute respiratory syndrome is an open access article distributed under coronavirus 2) appears to be responsible for several autoimmune complications. The occurrence the Creative Commons Attribution License, of autoimmune hemolytic anemia has been described in several case reports. This AIHA was also which permits unrestricted use, distribution, noticeable by the important number of blood transfusions required for COVID-19 (coronavirus and reproduction in any medium, provided the disease 2019) patients.
    [Show full text]
  • Package Insert
    Anti-Human Globulin Anti-IgG IH-Card AHG Anti-IgG (Rabbit)(Green)_____________________________________________________________________ English, B186359, Version 07, 2016.07 FOR IN VITRO DIAGNOSTIC USE Gel card for use with the IH-System MEETS FDA POTENCY REQUIREMENTS U.S. LICENSE NUMBER: 1845 Product-Identification: 74020 IH-Card AHG Anti-IgG: VOL 12 cards per box............ REF 813 420 100 VOL 48 cards per box............ REF 813 421 100 VOL 288cards per box........... REF 813 422 100 INTENDED USE The IH-Card AHG Anti-IgG is intended for the detection of antibodies on human red blood cells using the Direct and Indirect Antiglobulin Tests. SUMMARY Moreschi first described the use of Anti-Human Globulin in 1908.1 Coombs rediscovered the test in 1945.2,3 By injecting rabbits with human IgG, they were able to produce a protein (Anti-IgG) that reacted with ˝incomplete˝ antibodies (IgG). Most ˝incomplete˝ antibodies (IgG) fail to agglutinate red blood cells suspended in saline.4 Most clinically significant antibodies in red blood cell serology are of the IgG class and can only be detected by the use of Anti-IgG. The IH-Card AHG Anti-IgG is suitable for the Direct and Indirect Antiglobulin Tests. The Direct Antiglobulin Test allows the detection of in vivo sensitization of human red blood cells with immunoglobulins. The Indirect Antiglobulin Tests allows the detection of in vitro sensitization of human red blood cells with clinically significant antibodies. The Indirect Antiglobulin Test may be used for antibody detection, identification, IAT crossmatching , and D variant testing. An optional autocontrol may help to distinguish autoantibodies and alloantibodies.
    [Show full text]
  • Giant Cell Hepatitis with Autoimmune Hemolytic Anemia; a Case Report
    Iran J Pediatr Case Report Dec 2009; Vol 19 (No 4), Pp:421-424 Giant Cell Hepatitis with Autoimmune Hemolytic Anemia; a Case Report Mehri Najafi1, MD; Vajiheh Modarresi*1, MD; Kambiz Eftekhari1, MD; Fatemeh Mahjoub2, MD; Mina Izadyar1, MD 1. Department of Pediatrics, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, IR Iran 2. Department of Pathology, Tehran University of Medical Sciences, Tehran, IR Iran Received: Jan 30, 2009; Final Revision: Apr 25, 2009; Accepted: May 22, 2009 Abstract Background: Giant cell hepatitis (GCH) is a histological finding in infants with neonatal cholestasis and rarely can be seen after this period. Autoimmune hemolytic anemia (AIHA) which is characterized by massive and acute red blood cell destruction due to antibody production, responds favorably to corticosteroid therapy. The combination of GCH and AIHA is a rare distinct entity that carries poor response to immunosuppressive therapy and often progresses to fatal liver disease. Case Presentation: A 13‐month‐old boy was referred to us with anemia and icterus. Investigations confirmed the diagnosis of GCH which was associated with AIHA. Treatment with steroids and azathioprin failed. We changed to cyclosporine. The anemia improved by steroid and IVIG at the beginning, but few months later anemia relapsed. Finally he recovered with rituximab and now he is 6 years old in suitable condition. Conclusion: The association of AIHA with GCH is an uncommon condition that can be life threatening. Most patients initially respond to immunosuppressive agents, but usually recur and have an aggressive course. In this case liver disease responded to steroid and immunosuppressive therapy, but the AIHA was refractory to immunosuppressive therapy.
    [Show full text]
  • Plasmapheresis in a Child with Cold Antibody Autoimmune Hemolytic Anemia: Case Report
    Case Report Plasmapheresis in a child with cold antibody autoimmune hemolytic anemia: case report Zeynep Canan Özdemir1, Özcan Bör1, Ener Çağrı Dinleyici2, Eylem Kıral2 1Department of Pediatrics, Division of Pediatric Hematology/Oncology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey 2Department of Pediatrics, Division of Pediatric Intensive Care and Infectious Diseases, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey Cite this article as: Özdemir ZC, Bör Ö, Dinleyici EÇ, Kıral E. Plasmapheresis in a child with cold antibody autoim- mune hemolytic anemia: Case report. Turk Pediatri Ars 2017; 52: 169-72. Abstract Autoimmune hemolytic anemia is a picture of hemolysis which is caused by autoantibodies against red blood cell surface antigens. It is classified as primary, secondary or warm and cold autoimmune hemolytic anemia according to the temperature at which antibodies react. It is usually an acute and self-limiting condition. Here, we present a three-year-old male patient who presented with malaise, paleness, and dark-colored urine. His hemoglobin level was 5.8 g/dL, and increased indirect bilirubin and lactate dehydrogenase levels and decreased hap- toglobulin and reticulocyte levels were noted. A direct Coombs test was positive using anti-C3. Four erythrocyte suspension transfusions were given because the anemia was life-threatening. High-dose steroids (30 mg/kg/ day, methylprednisolone) and intravenous immunoglobulin (1 g/kg/day, two days) treatments were unresponsive. Plasmapheresis was performed and no further transfusions were needed after plasma- pheresis. Plasmapheresis treatment can be effective in children with cold type autoimmune hemolytic anemia. Key words: Autoimmune hemolytic anemia, cold antibody, plasmapheresis Introduction warm-antibody hemolytic anemia.
    [Show full text]
  • Direct Coombs Test
    Lab Dept: Transfusion Services Test Name: DIRECT COOMBS TEST General Information Lab Order Codes: DAT or DCAS (includes Direct Coombs and Antibody Screen, Indirect) or ABDC (includes Direct Coombs, ABO and Rh) Synonyms: Coombs Test; Direct, DAT; Coombs, Direct; Direct Antiglobulin Test CPT Codes: 86880 – Antihuman globulin test (Coombs), Direct Test Includes: Direct antiglobulin testing with polyspecific anti-human globulin serum. It may include use of monospecific (anti-IgG, anticomplement) when indicated. Logistics Test Indications: Useful for the detection of immunoglobulins (IgG) or complement adsorbed onto red cells. Used to detect autoimmune hemolytic anemias caused by antibody and/or complement components being bound to the patient’s red cells (including drug induced), transfusion reaction and erythroblastosis fetalis (hemolytic disease of the newborn). Coated red cells are said to be “sensitized”. In a DAT (Direct Antiglobulin/Coombs Test), the test is for antibody attached to the patient’s red cells in vivo. In an Antibody Screen (Indirect Antiglobulin Test), the antigen-antibody reaction occurs in vitro and one tests patient’s serum for antibody with reagent cells (the antigen). Refer to Direct Coombs/Antibody Screen or Type and Direct Coombs for alternative test combinations. Lab Testing Sections: Transfusion Services Phone Numbers: MIN: 612-813-6824 STP: 651-220-6558 Test Availability: Daily, 24 hours Turnaround Time: 4 – 24 hours Special Instructions: Provide diagnosis, transfusion history, and pertinent medications to the laboratory. Additional specimen may be requested if elution studies are indicated. Specimen Specimen Type: Whole blood Container: Lavender top tube (EDTA) Draw Volume: 0.5 mL blood (small EDTA) or 2 mL blood (large EDTA) Collection: All specimens submitted to the Transfusion Service must be appropriately labeled at the bedside with the time and date of collection, and the signature of the individual collecting the specimen.
    [Show full text]
  • Transfusion Services Test Name: TYPE and DIRECT COOMBS
    Lab Dept: Transfusion Services Test Name: TYPE AND DIRECT COOMBS General Information Lab Order Codes: ABDC Synonyms: Type and Coombs; ABO and Coombs; Type and DAT; ABO and DAT; ABO/Rh and Direct Coombs CPT Codes: 86900 – ABO 86901 – Rh 86880 - Direct Coombs Test Includes: ABO Group, Rh type and Direct Coombs (Direct Antiglobulin Test - DAT) Logistics Test Indications: Evaluating the presence of Hemolytic Disease of the Newborn (HDN) or evaluating the potential cause of other red cell hemolysis. Lab Testing Sections: Transfusion Service Phone Numbers: MIN Lab: 612-813-6824 STP Lab: 651-220-6558 Test Availability: Daily, 24 hours Turnaround Time: Blood Type: 30 minutes DAT: 4 – 24 hours Special Instructions: Provide diagnosis, transfusion history and pertinent medications to the laboratory. Additional specimen may be requested if elution studies are indicated. Specimen Specimen Type: Whole blood Container: Lavender top tube (EDTA) Draw Volume: 0.5 mL blood (small EDTA tube) or 2 mL blood (large EDTA tube) Collection: All specimens submitted to the Transfusion Service must be appropriately labeled at the bedside with the time and date of collection, and the signature of the individual collecting the specimen. A completed order, either through the HIS or general requisition must accompany each specimen. It is not always necessary to collect a new sample prior to the provision of blood for patients. Consult with the Transfusion Service prior to collecting additional samples if the patient status is unknown. Special Processing: Lab Staff: Refrigerate specimen Patient Preparation: Refer to Collection of Patient Specimens for full details. The patient must be positively identified when the specimen is collected.
    [Show full text]
  • Direct Coombs Test-Negative Autoimmune Hemolytic Anemia and Low-Affinity Igg Class Antibodies
    Direct Coombs test-negative autoimmune hemolytic anemia and low-affinity IgG class antibodies R.J. SOKOL, D.J. BOOKER, R. STAMPS, S. JALIHAL, AND B. PAUL Autoimmune hemolytic anemia, in which the direct antiglobulin test was no evidence of other disease or infection, a diagno- (DAT) is negative or weakly positive, may be due to low-affinity sis of AIHA was proposed. However, the DAT was autoantibodies. We describe two such cases. An 8-year-old male pre- sented with weight loss, jaundice, a hemoglobin of 33 g/L, reticulo- negative, even though crossmatching showed incompat- cytes of 306 x 109/L, and haptoglobin of < 0.1 g/L. The DAT was ibilities with all donor red blood cells (RBCs) tested. negative. After washing the red blood cells (RBCs) with saline at 4°C, Repeat testing after washing the red cells at 4°C showed the DAT was positive for IgG and an eluate contained an IgG3 autoan- tibody, thus confirming a diagnosis of autoimmune hemolytic anemia that the DAT test was, in fact, positive for IgG and a RBC (AIHA). Red cell transfusions and corticosteroids were given with eluate contained an IgG3 autoantibody. These findings eventual complete recovery. A 73-year-old male had a hemoglobin of confirmed the diagnosis of AIHA. The patient was treat- 89 g/L and haptoglobin of < 0.1 g/L. The DAT was initially negative but was positive for IgG using cold-washed (4°C) RBCs; it was also pos- ed with blood transfusions, prednisolone, and folic acid, itive with unwashed cells in the DiaMed system and an eluate con- with good effect.
    [Show full text]
  • Drug-Induced Immune Hemolytic Anemia: the Last 30 Years of Changes P
    George Garratty 1935–2014 Journal of Blood Group Serology and Molecular Genetics VOLUME 30, N UMBER 2, 2014 Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 30, Number 2, 2014 CONTENTS Introduction to Immunohematology Special Edition on 43 Drug-Induced Immune Cytopenias P.A. Arndt and R.M. Leger R EPORT 44 Drug-induced immune hemolytic anemia: the last 30 years of changes P. A . A r ndt R EPORT 55 Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms B.R. Curtis R EPORT 66 Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007 G. Garratty and P.A. Arndt C A SE R EPORT 80 Diagnostic pitfalls of drug-induced immune hemolytic anemia A. Salama and B. Mayer R EPORT 85 How we investigate drug-induced immune hemolytic anemia R.M. Leger, P.A. Arndt, and G. Garratty R EPORT 95 Drug-induced immune neutropenia/agranulocytosis B.R. Curtis 102 A NNOUNCEMENTS 105 A DVERT I SEMENTS 109 I NSTRUCT I ONS FOR A UTHORS E D I TOR - I N -C H I EF E D I TOR ia L B OA RD Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Thierry Peyrard, PharmD, PhD Pomona, California Paris, France M A N AG I NG E D I TOR Barbara J. Bryant, MD Mark Popovsky, MD Cynthia Flickinger, MT(ASCP)SBB Milwaukee, Wisconsin Braintree, Massachusetts Philadelphia, Pennsylvania Lilian Castilho, PhD S. Gerald Sandler, MD Campinas, Brazil Washington, District of Columbia TECHN I C A L E D I TORS Christine Lomas-Francis, MSc Martha R.
    [Show full text]